Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Research and Development
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development
MAJ Il y a 4 ans
Study to compare umeclidinium with glycopyrronium in COPD subjects
The primary objective of this study is to compare the efficacy and safety of UMEC 62.5 mcg with glycopyrronium 44 mcg in subjects with COPD over 12 weeks of treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
Testing eltrombopag in patients with acute myelogenous leukemia (AML) who receive chemotherapy with daunorubicin plus cytarabine
To assess the safety and tolerability of eltrombopag versus placebo in subjects receiving standard induction therapy for acute myeloid leukemia (AML)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency Time (IELT), Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Randomized, Double Blind, Placebo-Controlled, Parallel Group Study in Men with Premature Ejaculation
To determine if an on demand dosing of 50 or 150 mg of GSK557296 demonstrates superior efficacy with respect to duration of IELT during an 8 week study period compared to placebo in men with premature...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
Letrozol frente a Letrozol más Lapatinib (GW572016) en cáncer de mama hormosensible y operable, con HER-2 negativo. Estudio en Fase II aleatorizado y doble ciego con evaluación de biomarcadores. (Letrozole versus Letrozole plus lapatinib (GW572016) in hormone-sensitive, HER-2 negative operable breast cancer. A double blind randomized phase II study with biomarker evaluation)
To estimate the percentage of clinical objective response (cOR) (complete plus partial, measured by USG) in the breast
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
Study of a new thermostable formulation of Flolan™ to treat Pulmonary Arterial Hypertension (PAH)
• To describe the effect of the new thermo stable formulation of FLOLAN on quality of life in patients switching from the currently marketed FLOLAN to the new thermo stable formulation • To determine...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
A Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (ALS)
The primary objective is to assess the effect of ozanezumab on the physical function and survival of ALS subjects over a treatment period of 48 weeks. Function will be measured using the Amyotrophic ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A double-blind, randomised, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) on cerebral glucose utilisation and cognition in subjects with mild to moderate Alzheimer’s Disease (AD)
To compare changes in cerebral glucose metabolism in subjects receiving a 12- month course of Rosiglitazone XR to those receiving placebo, including the time course of any changes.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A phase II clinical study to assess the effectiveness, safety, tolerability and pharmacokinetics of inhaled GSK2339345 in patients with chronic cough using an aqueous droplet inhaler
EFFICACY: To evaluate the effect of a single dose of GSK2339345, administered on two occasions, four hours apart, versus placebo on objective cough counts in patients with chronic idiopathic cough.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 4 ans
A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma
The primary objective of this study is to evaluate the dose response, efficacy and safety of three doses of FF inhalation powder administered once daily in the evening to children aged 5-11 years with...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
Study PXN110527: The investigation of the efficacy and pharmacokinetics of XP13512 in subjects with neuropathic pain associated with post-herpetic neuralgia (PHN) who have had an inadequate response to gabapentin treatment
The primary objective of the study is to investigate the difference between two doses of XP13512 (3600 mg/day vs. 1200 mg/day) on pain intensity.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant